• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Germany-Based MilliporeSigma Expands Montgomery County, Maryland, Campus

MilliporeSigma, an international biosciences company, will expand its biosafety testing capacity in Montgomery County, Maryland. The $286 million project is expected to create 500 jobs over the next four years.

The company, known locally as BioReliance Corporation, currently has five locations in Rockville and is planning to consolidate in a new 250,000-square-foot facility at 9820 Darnestown Road at the Alexandria Center at Traville Gateway campus. MilliporeSigma will maintain one additional facility at 9630 Medical Center Drive.

“Our full contract testing services facility in Rockville will continue to serve as a hub for innovation to address current challenges and meet tomorrow’s demands,” said Benoit Gourdier, head of contract testing services at MilliporeSigma. “We look forward to continuing to grow here and to giving back to the Montgomery County community as we transform patients’ lives by ensuring the safety of the world’s medicine.”

To assist with the expansion, MilliporeSigma is eligible for a $1 million conditional loan through the Maryland Department of Commerce's Advantage Maryland (MEDAAF) program. Montgomery County is providing a $100,000 incentive package through a grant convertible to a loan under its Economic Development Fund. MilliporeSigma is also eligible for various state and local tax credits.

“We are truly thankful for MilliporeSigma’s dedication to doing business in Maryland,” noted Maryland Commerce Secretary Mike Gill. “Building this impressive new space in Rockville ensures the company will continue to flourish in Montgomery County for years to come.”

Merck Millipore was the brand used by Merck Group's global life science business until 2015 when the company rebranded. The company was formed when Merck acquired the Millipore Corporation in 2010.

Exclusive Research